Navigation Links
At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)
Date:4/15/2008

ve ahead quickly. Our proactive strategy is based on the wealth of our past experience and the unique opportunity that the natural health product market represents to meet the needs of those who could benefit from this product, while helping to fund our longer-term drug development programs geared to future growth," he stated.

"I am particularly pleased to have regained full ownership of KIACTA(TM) given the promising results from our Phase II/III trial and our intention to initiate another Phase III trial and complete the development of this product candidate," Dr. Bellini concluded.

OVOS Natural Health - Launch activities in preparation for VIVIMIND(TM)

Fifteen years of combined scientific research including clinical trials with over 2,000 individuals in Canada, the United States and Europe and millions of dollars invested lie behind OVOS Natural Health's claim that VIVIMIND(TM) can help protect memory function and reduce age-associated brain volume loss normally leading to cognitive problems. The Company is looking to the natural health product market to make homotaurine, a naturally occurring ingredient otherwise found in algae available to the public given its good safety and tolerability profiles and the wealth of data supporting the impact on memory function and brain structures associated with memory and learning.

Following post-hoc analyses, the results in previous human testing clearly showed that homotaurine had a statistically significant dose-dependent effect and reduced by at least 68% (p-value 0.035) the loss of hippocampal volume over time in the individuals tested when compared to the untreated group. An almost statistically significant clinical benefit equivalent to 33% less decline (p-value: 0.065) on their cognitive tests as measured by ADAS-cog was also observed in individuals receiving homotaurine. The launch activities for VIVIMIND(TM) are in preparation.

"No other product on the natural health product market
'/>"/>

SOURCE NEUROCHEM INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Otter Tail Corporation Holds 2008 Annual Meeting: Shareholders Elect Directors; Board Declares Quarterly Dividend
2. Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research
3. Northwest Hospital & Medical Center Hosts Health & Wellness Pavilion At Second Annual King 5 Healthy Living Expo
4. European Society of Human Reproduction & Embryology 24th annual meeting
5. Media advisory - Neurochems Annual and Special Meeting of Shareholders April 15, 2008
6. Neurochem Annual and Special Meeting of shareholders
7. With annual deaths from malaria on the rise: Scientists ask where is all the money going?
8. China Medical Technologies to Announce 4QFY2007 Financial Results, Declare Annual Cash Dividend and Provide FY2008 Annual Targets on June 12, 2008
9. HealthMEDX Hosts Annual User Group Conference
10. Abaxis to Present at the SunTrust Robinson Humphreys 37th Annual Institutional Unconference
11. Access Pharmaceuticals to Present New Data on ProLindac(TM) at the AACR Annual Meeting 2008 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 29, 2015 Intermountain Healthcare ... with Stratus Video Interpreting for ... better communication and timely care for patients ... loss. Stratus’ video remote interpreting (VRI) services ... staff to quickly access qualified medical interpretation ...
(Date:5/29/2015)... 29, 2015 The print component of ... circulation of approximately 250,000 and an estimated readership of ... vast social media strategy, and across a network of ... digital version of the campaign, click here. ... publication. Inside, the actress, model and producer details her ...
(Date:5/29/2015)... 2015 Mediaplanet has joined forces with ... Skin Health is a cross-platform campaign with a ... of New York, Los Angeles, and Chicago, the campaign ... digital counterpart will reach a national audience through one ... the Skin Health campaign and Colorescience, click here ...
(Date:5/29/2015)... OncLive proudly announces the 2015 ... recognized by a panel of eminent oncologists for landmark ... Honorees will be introduced and celebrated TONIGHT at the ... 8:30-11:00 p.m. CDT at The Chicago Illuminating Company, 2110 ... recognized for groundbreaking accomplishments, in fields including translational research, ...
(Date:5/29/2015)... May 29, 2015 Healthpointe is ... with specialists, physical therapy, and injections , For ... back and/or lower back pain, Healthpointe has a ... for herniated discs, disc protrusions and other causes ... , Healthpointe’s team of renowned surgeons are now ...
Breaking Medicine News(10 mins):Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 2Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 3Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 4Health News:Mediaplanet Launches “Skin Health” Campaign Featuring Colorescience 2Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 2Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 3Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 4Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 3
... University of Texas MD Anderson Cancer Center has been awarded ... caused by head and neck cancer radiation treatment, can be ... The $2.7 million grant awarded by the National Cancer ... a perfect score from peer scientists evaluating grant proposals for ...
... Doheny HealthDay Reporter , TUESDAY, March 22 ... for the recommended five years protects women from breast ... drug and it also shields some women from cardiovascular ... heart-disease risk reduction were noted 15 years after starting ...
... 22 (HealthDay News) -- Nurses often don,t speak up ... workers making mistakes that could harm patients, new research ... steps to reduce medical errors through measures such as ... automated medication-dispensing systems. But the study, which included ...
... Jenifer Goodwin HealthDay Reporter , TUESDAY, March 22 ... called fibrates is on the rise in the United States ... improve health, researchers say. Fibrates are often prescribed to ... high levels of triglycerides, a harmful form of fat circulating ...
... work in Lewy body dementia , the Harry T. ... gift, pledged over four years. Lewy body dementia, which combines ... , is the second most common form of dementia in ... and video resources, including excerpts from an interview with Drs. ...
... University has started recruiting patients for a new ... whether the cholesterol-reducing drug rosuvastatin is effective in ... laboratory research and population studies have shown that ... lowers cholesterol, had fewer colon polyps, which can ...
Cached Medicine News:Health News:UT MD Anderson receives grant for study of acupuncture in cancer 2Health News:Tamoxifen May Offer Long-Term Heart, Cancer Protection 2Health News:Tamoxifen May Offer Long-Term Heart, Cancer Protection 3Health News:Study: Reluctance to Speak Up Encourages Medical Errors 2Health News:Study Questions Rise in Use of Certain Cholesterol Drugs 2Health News:Study Questions Rise in Use of Certain Cholesterol Drugs 3Health News:Study Questions Rise in Use of Certain Cholesterol Drugs 4Health News:Gift will allow Mayo researchers to explore cause of dementia in the elderly 2Health News:Gift will allow Mayo researchers to explore cause of dementia in the elderly 3Health News:Jefferson clinical trial: Can a cholesterol drug prevent colon cancer? 2
(Date:5/29/2015)... MENLO PARK, Calif. , May 29, ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical ... therapies in new orphan drug indications, presented additional ... Cancer Research (AACR) Advances in Brain Cancer Research ... product candidate VAL-083 (dianhydrogalactitol) to treat ...
(Date:5/29/2015)... OAKS, Calif. , May 29, 2015 /PRNewswire/ ... pooled data from two pivotal Phase 3, global, ... calcimimetic, for the treatment of secondary hyperparathyroidism (SHPT) ... hemodialysis. Both studies met the primary endpoint, demonstrating ... AMG 416 groups achieved a greater than 30 ...
(Date:5/28/2015)... , May 28, 2015  Eli Lilly and Company ... its previously announced cash tender offer for up to $1.6 ... securities. Holders of notes who tendered, and did ... New York City time, on May ... for purchase by Lilly, are eligible to receive the total ...
Breaking Medicine Technology:DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5
... (Nasdaq: MYL ) today confirmed that the ... Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation in connection with ... with the U.S. Food and Drug Administration (FDA) for ... 0.05 mg/day, 0.075 mg/day and 0.1 mg/day. This product ...
... would tax the companies that manage prescription drug benefits ... owners they contract with – will drive up prescription ... Management Association (PCMA), the trade group for America,s pharmacy ... of America,s businesses, state and federal government agencies, and ...
Cached Medicine Technology:Mylan Confirms First-to-File Patent Challenge Relating to Vivelle-Dot® 2PCMA: Mississippi's 'Secret Prescription Drug Tax' Will Raise Costs 2
Inquire...
...
VACUETTE Trace Element tubes - Ridged (safety screw cap) are designed to test trace elements such as Cu, Zn, Pb, etc....
Inquire...
Medicine Products: